HCW Biologics (HCWB) Free Cash Flow (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Free Cash Flow data on file, last reported at -$3.4 million in Q4 2025.

• Quarterly Free Cash Flow fell 13.81% year-over-year to -$3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13.4 million (up 7.57% YoY) and the FY2025 annual result came in at -$13.4 million, up 7.57% from the prior year.
• Free Cash Flow retreated to -$3.4 million in Q4 2025, from -$3.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $6.4 million in Q4 2022 to a low of -$12.5 million in Q3 2022.
• A 5-year average of -$3.8 million and a median of -$3.3 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 288.93% — and 2023, when it sank 321.89%.
• Tracing HCWB's Free Cash Flow over 5 years: stood at -$3.4 million in 2021, then soared by 288.93% to $6.4 million in 2022, then sank by 194.12% to -$6.0 million in 2023, then jumped by 51.18% to -$2.9 million in 2024, then slipped by 13.81% to -$3.4 million in 2025.
• The last three Free Cash Flow figures came in at -$3.4 million (Q4 2025), -$3.2 million (Q3 2025), and -$3.3 million (Q2 2025), per Business Quant data.